» Articles » PMID: 22406913

Lysergic Acid Diethylamide (LSD) for Alcoholism: Meta-analysis of Randomized Controlled Trials

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2012 Mar 13
PMID 22406913
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36-2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I² = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Citing Articles

American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.

Barnett B, Arakelian M, Beebe D, Ontko J, Riegal C, Siu W Psychedelic Med (New Rochelle). 2025; 2(1):1-9.

PMID: 40051760 PMC: 11658671. DOI: 10.1089/psymed.2023.0036.


Licit use of illicit drugs for treating depression: the pill and the process.

Torrado Pacheco A, Moghaddam B J Clin Invest. 2025; 134(12).

PMID: 40047885 PMC: 11178541. DOI: 10.1172/JCI180217.


Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.

Myran D, Xiao J, Fabiano N, Pugliese M, Kaster T, Rosenblat J CMAJ. 2025; 197(8):E204-E213.

PMID: 40032291 PMC: 11879370. DOI: 10.1503/cmaj.241191.


The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.

Hogea L, Tabugan D, Costea I, Albai O, Nussbaum L, Cojocaru A Medicina (Kaunas). 2025; 61(2).

PMID: 40005395 PMC: 11857248. DOI: 10.3390/medicina61020278.


Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?.

Villiger D Int Rev Psychiatry. 2025; 36(8):869-878.

PMID: 39980214 PMC: 11854054. DOI: 10.1080/09540261.2024.2357669.